CNS pipeline · person
Inderjit Kaul, MD, MPH
Member of the Minerva Neurosciences Board of Directors since November 2025 and a member of its Scientific Advisory Board. Chief Medical Officer of Draig Therapeutics; previously led late-stage neuropsychiatry development at Bristol Myers Squibb and the development of the muscarinic agonist that became Cobenfy at Karuna Therapeutics. Holds an MD and an MPH from Harvard University.
- 1 company
Current roles
- Minerva Neurosciences, Inc.Director · Board2025–present
- Minerva Neurosciences, Inc.Scientific Advisory Board Member · Advisor2026–present
Appears with
People sharing a company with Inderjit.
- Avi Reichenberg · Minerva Neurosciences, Inc.
- Brian Kirkpatrick · Minerva Neurosciences, Inc.
- David Kupfer · Minerva Neurosciences, Inc.
- Fouzia Laghrissi-Thode · Minerva Neurosciences, Inc.
- Frederick Ahlholm · Minerva Neurosciences, Inc.
- Greg Strauss · Minerva Neurosciences, Inc.
- Hans Peter Hasler · Minerva Neurosciences, Inc.
- Jan van Heek · Minerva Neurosciences, Inc.
- Jim O'Connor · Minerva Neurosciences, Inc.
- Joseph Reilly · Minerva Neurosciences, Inc.
- Michael Davidson · Minerva Neurosciences, Inc.
- Oliver Howes · Minerva Neurosciences, Inc.
- Philip Harvey · Minerva Neurosciences, Inc.
- Remy Luthringer · Minerva Neurosciences, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.